Breaking News

Burning Rock, IMPACT Therapeutics Partner on Testing Services for IMP9064

To provide testing services from CLIA labs in China and U.S. for IMPACT’s ATR inhibitor IMP9064 for Phase I/II clinical study.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Burning Rock Biotech Ltd. entered a collaboration with IMPACT Therapeutics to provide testing services for IMPACT’s development of its ATR inhibitor IMP9064, which received IND clearance from the U.S. FDA for the Phase I/II clinical study. The collaboration will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S.   IMP9064 is an ATR inhibitor discovered and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters